Loading...
Rapid AAV-Neutralizing Antibody Determination with a Cell-Binding Assay
Guo, Ping Huang, Jianhe Chew, Helen Sang, Nianli Diao, Yong
Guo, Ping
Huang, Jianhe
Chew, Helen
Sang, Nianli
Diao, Yong
Citations
Altmetric:
Genre
Journal article
Date
2019-01-02
Advisor
Committee member
Department
Microbiology and Immunology
Clinical Sciences
Clinical Sciences
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.1016/j.omtm.2018.11.007
Abstract
Recombinant adeno-associated virus (rAAV) has been developed as a successful vector for both basic research and human gene therapy. However, neutralizing antibodies (NAbs) against AAV capsids can abolish AAV infectivity on target cells, reducing the transduction efficacy. Absence of AAV NAb has become a prerequisite qualification for patients enrolled in gene therapy trials. Nevertheless, accurate assessment of AAV NAb has remained a challenging task. Here we developed a rapid assay based on the observations that AAV NAb inhibits rAAV binding to the host cell surface and NAb titers are negatively related to the amount of AAV genomes binding to the target cells. By quantifying the AAV genome on the target cells in the presence of anti-sera, AAV NAb titers can be accurately determined. The titer determined by this assay correlates well with the classical transduction-based assays. A major advantage of this method is that it can be carried out with a 30-min binding assay without the lengthy wait for a transduction outcome. This assay is independent of transduction performance of AAV serotype in the target cells. Therefore, the AAV cell-binding assay for NAb determination offers an alternative method for in vivo NAb assay.
Description
Citation
Citation to related work
Cell Press
Has part
Molecular Therapy - Methods and Clinical Development, Vol. 13
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu